About Genprex
Genprex is a company based in Austin (United States) founded in 2009. Genprex has raised $3.11 million across 9 funding rounds from investors including NIH and Inception Capital Management. The company has 15 employees as of December 31, 2024. Genprex offers products and services including Oncoprex® Delivery System, Reqorsa® Gene Therapy, and GPX-002. Genprex operates in a competitive market with competitors including Insulet, Kriya Therapeutics, Sana Biotechnology, Poseida Therapeutics and Semma Therapeutics, among others.
- Headquarter Austin, United States
- Employees 15 as on 31 Dec, 2024
- Stage Public
-
Sectors
Healthcare
-
Email
Locked
-
Phone
Locked
-
Website
Locked
-
Social
Locked
- Legal Name Genprex, Inc.
-
Annual Revenue
Not available
-
Net Profit
-$21.11 M (USD)31.59as on Dec 31, 2024
-
EBITDA
-$21.17 M (USD)31.85as on Dec 31, 2024
-
Total Equity Funding
$3.11 M (USD)
in 9 rounds
-
Latest Funding Round
$2.59 M (USD), Grant
Jul 21, 2020
-
Investors
NIH
& 1 more
-
Employee Count
15
as on Dec 31, 2024
Unlock complete access to The Company Check
Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.
- Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
- Full access to every database India & global coverage, advanced filters and rich profile details
- Always-on access from your team account Single premium plan for everything you see on the portal
IPO & Listings of Genprex
Genprex is a publicly listed company on the NASDAQ with ticker symbol GNPX in USA, operating in the Health technology sector. As a publicly traded entity, the company provides investors with opportunities to participate in its growth story through equity ownership. The listing enables access to capital markets, enhances corporate visibility, and provides liquidity for shareholders while maintaining transparency through regulatory compliance and regular financial disclosures.
Products & Services of Genprex
Genprex offers a comprehensive portfolio of products and services, including Oncoprex® Delivery System, Reqorsa® Gene Therapy, and GPX-002.
System for delivering genes to treat cancer effectively
Therapy reintroducing genes to suppress tumors in patients
Treatment targeting cancer and diabetes through gene administration
People of Genprex
Unlock access to complete
Unlock access to complete
Funding Insights of Genprex
Genprex has successfully raised a total of $3.11M across 9 strategic funding rounds. The most recent funding activity was a Grant round of $2.59 million completed in July 2020. This substantial capital infusion reflects strong investor confidence in the company's business model, growth potential, and market opportunities. The funding enables strategic expansion, product development, market penetration, and operational scaling to drive long-term value creation and competitive advantage.
Investors in Genprex
Genprex has secured backing from 2 investors, including institutional and venture fund investors. Prominent investors backing the company include NIH and Inception Capital Management.
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
|
PE firm investments are directed toward US and Australia opportunities.
|
Locked | Locked | Locked | |
|
Drug discovery services are provided to the biopharma sector.
|
Locked | Locked | Locked |
Investor details for Genprex
Investor domains, locations, round participation, and complete history require an active premium plan.
- Investor domains
- Investor locations
- Funding rounds
- Participation history
Verified entity values are shown only after access is granted.
Investments & Acquisitions by Genprex
Investment portfolio details for Genprex
Portfolio company identities, transaction dates, round details, and investment values require an active premium plan.
- Portfolio identities
- Transaction dates
- Round details
- Investment values
Verified entity values are shown only after access is granted.
Financial Statements - Genprex
Detailed financials for Genprex
Historical revenue, profit, statement rows, ratios, and trend charts require an active premium plan.
- Historical revenue
- Profit trends
- Statement rows
- Financial ratios
Verified entity values are shown only after access is granted.
Genprex Comparisons
Peer comparison for Genprex
Named peer metrics, headcount, funding, location, and side-by-side benchmarks require an active premium plan.
- Named peers
- Headcount comparison
- Funding comparison
- Operating benchmarks
Verified entity values are shown only after access is granted.
Competitors of Genprex
Genprex operates in a dynamic and competitive business environment, facing competition from various established players and emerging companies in the market. The competitive landscape includes prominent companies such as Insulet, Kriya Therapeutics, Sana Biotechnology, Poseida Therapeutics and Semma Therapeutics, among others.
| Company Name | Domain | Founded year | HQ Location | Description |
|---|---|---|---|---|
| Locked | Locked | Locked |
Wearable insulin infusion systems are developed for diabetes patients.
|
|
| Locked | Locked | Locked |
Developer of therapeutic solutions for the treatment of diabetes
|
|
| Locked | Locked | Locked |
Genetically engineered cell therapies are developed for multiple disorders.
|
|
| Locked | Locked | Locked |
Developer of gene therapies for treating cancer and liver orphan disease by using gene editing technologies
|
|
| Locked | Locked | Locked |
Provider of bio-artificial pancreas for Type 1 Diabetes treatment
|
|
| Locked | Locked | Locked |
Cell-based therapies for cancer treatment are developed.
|
Detailed competitors of Genprex
Competitor domains, locations, full profiles, and operating metrics require an active premium plan.
- Domains and locations
- Full company profiles
- Operating metrics
- Competitive positioning
Verified entity values are shown only after access is granted.
Latest news on Genprex
Complete news archive for Genprex
Full article history, source details, and older brand coverage require an active premium plan.
- Full article archive
- Source and publication date
- Older coverage
- Brand-specific news history
Verified entity values are shown only after access is granted.
Frequently Asked Questions about Genprex
Genprex was founded in 2009 and raised its 1st funding round 4 years after it was founded.
Genprex is headquartered in Austin, United States. It is registered at Austin, Texas, United States.
Genprex is a funded company, having raised a total of $3.11M across 9 funding rounds to date.
As of Dec 31, 2024, the latest employee count at Genprex is 15.
Founded in 2009 and based in Austin, United States, operations in the biotechnology sector are focused on cancer therapeutics. Molecular-level treatments, including the lead candidate Oncoprex combined with erlotinib, are designed to induce apoptosis in cancer cells and regulate signaling and inflammatory pathways. These therapies target non-small cell lung cancer and metastases, with delivery via injection.
Genprex's top competitors include Insulet, Senti Biosciences and Sana Biotechnology.
Genprex offers Oncoprex® Delivery System, Reqorsa® Gene Therapy, and GPX-002.
Yes, Genprex is publicly traded on NASDAQ under the ticker symbol GNPX.
Genprex has 2 investors. Key investors include NIH, and Inception Capital Management.
The ticker symbol of Genprex is GNPX on NASDAQ.